Quadrature Capital’s West Pharmaceutical WST Stock Holding History

Quadrature Capital’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,973	Closed	-$646K	–	1537
2024 Q4	$646K	Buy	+1,973	New	+$621K	0.01%	522
2023 Q1	–	Sell	-37,382	Closed	-$8.8M	–	1208
2022 Q4	$8.8M	Buy	+37,382	New	+$8.86M	0.26%	93
2021 Q2	–	Sell	-1,300	Closed	-$366K	–	1262
2021 Q1	$366K	Buy	+1,300	New	+$372K	0.02%	565
2020 Q4	–	Sell	-1,400	Closed	-$385K	–	1094
2020 Q3	$385K	Buy	+1,400	New	+$370K	0.02%	532
2020 Q2	–	Sell	-6,288	Closed	-$959K	–	834
2020 Q1	$959K	Buy	6,288 +592	+10%	+$91.1K	0.23%	128
2019 Q4	$856K	Buy	+5,696	New	+$829K	0.03%	295
2019 Q3	–	Sell	-5,960	Closed	-$745K	–	688
2019 Q2	$745K	Buy	+5,960	New	+$703K	0.05%	263
2017 Q3	–	Sell	-19,417	Closed	-$1.83M	–	679
2017 Q2	$1.83M	Buy	+19,417	New	+$1.79M	0.14%	165

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DCP

Durable Capital Partners Bethesda, Maryland $10.3B AUM 29.04% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Quadrature Capital's WST Position: Q1 2025 in Review

Quadrature Capital sold out of West Pharmaceutical (WST) in Q1 2025, closing a stake of 1,973 shares — an estimated $646K sold.

Quadrature Capital first reported a position in WST in Q2 2017 and held it in 8 quarters. The position peaked at $8.8M in Q4 2022. 715 funds tracked by Wall St. Rank hold WST as of Q1 2025.

Quadrature Capital reported no remaining West Pharmaceutical position as of Q1 2025 after selling out during the quarter.
Quadrature Capital sold 1,973 West Pharmaceutical shares in Q1 2025, an estimated $646K.
Quadrature Capital first reported a position in West Pharmaceutical in Q2 2017 and held it in 8 quarters.
Quadrature Capital's West Pharmaceutical position peaked at $8.8M in Q4 2022.
715 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2025.

Based on Quadrature Capital's 13F filing for Q1 2025, filed 13 May 2025.